Wireless EEG and Attention Evaluation System for ADHD

描述（由申请人提供）：本项目的总体目标是开发一种高度便携和定量的神经行为注意力评估设备（NeuroADTM），用于识别和定量评估患有注意力缺陷多动障碍（ADHD）的儿童/成人以及患有与睡眠呼吸障碍（SDB）相关的ADHD样症状的儿童的药物/治疗。ADHD和SDB是儿童中相对常见的问题。打鼾、ADHD和SDB的患病率分别为10%、7%和2%。此外，最近的研究表明，15-25%的ADHD诊断可能是继发于未被识别的SDB。目前还没有独立的ADHD诊断测试，目前的诊断方法有些主观。NeuroAD通过将高度便携的多通道无线EEG采集和分析设备与基于神经病学的注意力测试和先进的信号处理算法相结合，提供了一种客观、实用和定量的评估ADHD的方法。15分钟的测试方案可以在几乎任何地点（初级保健医生/儿科医生办公室/诊所、精神病医生办公室/诊所等）进行。第一阶段的工作涉及在许多正常和ADHD儿童和成人的临床研究中成功实施Multi-EEG NeuroADTM。NeuroADTM的新算法和判别指数将联合收割机EEG相关变量与行为反应特征相结合，已被证明在区分正常儿童与ADHD和ADHD样症状儿童方面非常有效。第二阶段的工作重点是完成和微调第一阶段开发的硬件/软件/算法。此外，我们将开发NeuroADTM，这将是一个小型化的配置，使用NeuroADTM的硬币大小的脑电图设备。这种高度便携和易于使用的设备将利用一个商业手持PDA沿着一个易于连接的头带，用于快速方便地放置电极。该系统将对成人和儿童受试者（正常、ADHD用药前后和SDB腺样体扁桃体切除术前后）进行广泛的多中心临床评价。这些测试的结果将被分组在一起进行全面的统计分析，以证明NeuroADTM在筛查和识别ADHD以及评估药物/治疗效果方面的有效性。本项目正在开发的神经行为注意力评估设备（NeuroADTM）旨在作为一种流动的、易于使用的、高度定量的方法来筛查ADHD的存在并评估药物/治疗的效果。15分钟的测试几乎可以在任何地点进行（初级保健医生/儿科医生办公室/诊所，精神科医生办公室/诊所等）。并且具有将ADHD与由睡眠呼吸暂停和其他睡眠呼吸障碍引起的ADHD样症状区分开的潜力。

DESCRIPTION (provided by applicant): The overall aim of this project is to develop a highly portable and quantitative Neurobehavioral Attention Evaluation Device (NeuroADTM) for the identification and quantitative evaluation of medication/therapy in children/adults with attention deficit hyperactivity disorder (ADHD), as well as children with ADHD-like symptoms related to sleep disordered breathing (SDB). ADHD and SDB are relatively common problems in children. The prevalence of snoring, ADHD, and SDB are 10%, 7%, and 2% respectively. Furthermore, recent studies have suggested that 15-25% of ADHD diagnoses may be secondary to unrecognized SDB. There is currently no independent diagnostic test for ADHD and the current method of diagnosis is somewhat subjective. NeuroAD provides an objective, practical, and quantitative means of assessing ADHD by combining a highly portable multi-channel wireless EEG acquisition and analysis device with an auditory-based test of attention and advanced signal processing algorithms. The 15 minute test protocol can be administered at virtually any location (primary care physician/pediatrician office/clinic, psychiatrists' office/clinic, etc.). Phase I effort involved the successful implementation of the Multi-EEG NeuroADTM in a number of clinical studies with both normal and ADHD, children and adults. NeuroADTM s novel algorithms and discriminating indices, which combine EEG-related variables with the profile of the behavioral response, have been shown to be very effective in distinguishing normal children from children with ADHD and ADHD-like symptoms. Phase II effort centers around finalizing and fine-tuning the hardware/software/algorithms developed in Phase I. In addition, we will develop NeuroADTM which will be a miniaturized configuration using NeuroADTM s coin-sized EEG device. This highly portable and easy-to-use device will utilize a commercial hand-held PDA along with an easy-to-attach headband for fast and convenient placement of the electrodes. This system will undergo extensive multi-center clinical evaluations with adult and children subjects (normal, ADHD pre- and post-medication, and SDB pre- and post-adenotonsillectomy). The results of these tests will be grouped together to perform a comprehensive statistical analysis to demonstrate the effectiveness of NeuroADTM in screening and identifying of ADHD and evaluating the effects of medication/therapy. The Neurobehavioral Attention Evaluation Device (NeuroADTM) that is being developed under this project is aimed to be utilized as an ambulatory, easy-to-use, and highly quantitative method to screen for the presence of ADHD and evaluating the effects of medication/therapy. The 15-minute test can be administered at virtually any location (primary care physician/pediatrician office/clinic, psychiatrists' office/clinic, etc.) and has the potential to differentiate ADHD from ADHD-like symptoms caused by sleep apnea and other sleep disordered breathing.